NEW YORK (360Dx) – Liquid biopsy company Angle this week reported interim financial results for the six months ended Oct. 31, 2017. The firm's revenues for H2 2017 were £200,000 ($283,286), equivalent to its revenues in H1 2017. Angle also reported a loss from continuing operations of £3.4 million and a cash balance of £4.3 million as of Oct. 31. The firm further said it now has an installed base of more than 145 Parsortix instruments deployed worldwide, up from 120 installed instruments in H1 2017, and completed more than 39,000 blood separations in the second half of the year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.